Amgen invests $1B into North Carolina facility
Thousand Oaks-based Amgen continued its investment in its manufacturing facility in North Carolina, as the company announced a $1 billion investment on Dec. 4 to establish a second drug substance manufacturing facility.
This brings the company’s total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
“This expansion underscores our unwavering focus on bringing transformative medicines to patients around the world,” Robert A. Bradway, chairman and CEO at Amgen, said in a press release.
“North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact.”
The $1 billion facility will incorporate cutting-edge technologies and sustainable practices, aligning with Amgen’s commitment to environmental stewardship and manufacturing excellence, according to a press release.
In tandem with the existing facility, these investments will create 370 new jobs in the region, supporting a robust biomanufacturing hub.
“North Carolina’s reputation as one of the world’s leading centers for biotechnology soars even higher with today’s decision by Amgen,” said North Carolina Governor Roy Cooper. “North Carolina offers everything an innovative biotech company needs to succeed, especially our highly trained, dedicated and diverse workforce which is fine-tuned to the needs of this critical industry.”
email: [email protected]
